posted on 2019-12-03, 16:05authored byBenjamin W. Stein, Amanda Morgenstern, Enrique R. Batista, Eva R. Birnbaum, Sharon E. Bone, Samantha K. Cary, Maryline G. Ferrier, Kevin D. John, Juan Lezama Pacheco, Stosh A. Kozimor, Veronika Mocko, Brian L. Scott, Ping Yang
A major chemical challenge facing implementation of 225Ac in targeted alpha therapyan emerging technology
that has
potential for treatment of diseaseis identifying an 225Ac chelator that is compatible with in vivo applications.
It is unclear how to tailor a chelator for Ac binding because Ac coordination
chemistry is poorly defined. Most Ac chemistry is inferred from radiochemical
experiments carried out on microscopic scales. Of the few Ac compounds
that have been characterized spectroscopically, success has only been
reported for simple inorganic ligands. Toward advancing understanding
in Ac chelation chemistry, we have developed a method for characterizing
Ac complexes that contain highly complex chelating agents using small
quantities (μg) of 227Ac. We successfully characterized
the chelation of Ac3+ by DOTP8– using
EXAFS, NMR, and DFT techniques. To develop confidence and credibility
in the Ac results, comparisons with +3 cations (Am, Cm, and La) that
could be handled on the mg scale were carried out. We discovered that
all M3+ cations (M = Ac, Am, Cm, La) were completely encapsulated
within the binding pocket of the DOTP8– macrocycle.
The computational results highlighted the stability of the M(DOTP)5– complexes.